Literature DB >> 6740836

Cytomorphological and histological studies on the urothelium during and after chemoimmune prophylaxis.

H D Adolphs, H W Schwabe, B Helpap, C Volz.   

Abstract

During and after chemoimmune prophylaxis with i.v. cyclophosphamide (CTX) and both intravesical and systemic BCG-treatment, the bladder mucosa is prone to morphological changes which might resemble tumor recurrences. Therefore, morphological parameters which can discriminate between treatment effects and tumor recurrences are of interest. In a prospective study, routine cytology, determination of granulocytes, lymphocytes, and macrophages in the urine sediment as well as flow-cytophotometry (FCM) for DNA analysis were performed before, during, and after chemoimmune prophylaxis. In addition, bladder biopsies and all recurrent tumors were histologically analysed. Our results show that FCM is the best method for monitoring the bladder mucosa for recurrent tumors during treatment. After termination of BCG, it takes at least 4 months for cytological normalization to take place. Urine excretion of granulocytes, lymphocytes, and macrophages does not correlate with this process. Histological alterations during treatment are demonstrated; their normalization requires at least 3 months. In 10% of the patients chronic inflammatory lesions ("pseudotumors") develop.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6740836     DOI: 10.1007/BF00257179

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  8 in total

1.  Automated flow cytometry to monitor intravesical BCG therapy of superficial bladder cancer.

Authors:  F A Klein; H W Herr; W F Whitmore; C H Pinsky; H T Oettgen; M R Melamed
Journal:  Urology       Date:  1981-04       Impact factor: 2.649

2.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

3.  Chemoimmune prophylaxis of superficial bladder cancer.

Authors:  H D Adolphs; H P Bastian
Journal:  J Urol       Date:  1983-01       Impact factor: 7.450

4.  Chemoimmune prophylaxis of superficial bladder tumors: results after treatment of 130 patients in 4 years.

Authors:  H D Adolphs; H P Bastian
Journal:  Urol Res       Date:  1983

5.  Improved application of impulse cytophotometry for the diagnosis of urinary bladder carcinoma.

Authors:  H W Schwabe; H D Adolphs
Journal:  Urol Res       Date:  1982

6.  BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses.

Authors:  D L Lamm; D E Thor; W D Winters; V D Stogdill; H M Radwin
Journal:  Cancer       Date:  1981-07-01       Impact factor: 6.860

7.  Bladder cancer immunotherapy.

Authors:  D L Lamm; D E Thor; V D Stogdill; H M Radwin
Journal:  J Urol       Date:  1982-11       Impact factor: 7.450

8.  Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.

Authors:  S A Brosman
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450

  8 in total
  1 in total

1.  Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.

Authors:  E C De Boer; W H De Jong; A P Van Der Meijden; P A Steerenberg; J A Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.